Aspartate Beta-Hydroxylase (ASPH) level of expression and clinical significance in Acute Myeloid Leukemia

Abstract

The aim of this study was to assess the level of expression of Aspartate Beta- Hydroxylase (ASPH) in serum of Egyptian AML patients and study its clinical significance. The study included 30 AML patients and 10 healthy control subjects. The patients were recruited from attendants of the Clinical Hematology and Oncology Unit, Internal Medicine Department, Ain Shams University during the period from August 2019 to March 2020. Patients were included if were aged 16 years and have newly diagnosed AML. AML patients were subjected to full history taking, thorough clinical examination and routine investigations including complete blood count, kidney and liver function tests, LDH, and coagulation profile. Bone marrow aspiration was done for morphologic examination and cytogenetic and molecular studies. Immunophenotyping was done by immunohisto- chemistry or flowcytometry. Radiographic studies were done for assessment of extramedullary disease. Cerebrospinal fluid examination was done in cases of FAB M4-5 subtypes or if signs of CNS infiltration existed. Measurement of human Aspartyl/Asparaginyl Beta-hydroxylase level (ASPH) in serum using ELISA Kit in patients at time of diagnosis and in the ten healthy persons. The patients' status were assessed at day 28 for remission state in response to induction therapy with the combination of 3+7 regimen. Only one patient relapsed till the end of the study from the remitted alive patients.